RE:RE:RE:actuarial...Unfortunately, this is not going to be a quick "win" stock. If it can survive to the point of FDA approval for the three potential pipelines, it would be a big win. Otherwise, it dies soon due to lack of financing capability. Therefore, the ability of generating revenue to finance its R&D become key important. We see some good signs / progress. Hopefully, it can keep its momentum.